Madan, Ravi A.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 406

Phase i trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma

Bilusic, M., Heery, C. R., Arlen, P. M., Rauckhorst, M., Apelian, D., Tsang, K. Y., Tucker, J. A., Jochems, C., Schlom, J., Gulley, J. L., et al. (2014) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesBacterial Cancer Therapy

Cited by 102

A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.

Karzai, F., Madan, R. A., Owens, H., Couvillon, A., Hankin, A., Williams, M., Bilusic, M., Cordes, L. M., Trepel, J. B., Killian, K., et al. (2018) · Journal of Clinical Oncology

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 50

A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver

Gulley, J. L., Madan, R. A., Tsang, K.-Y., Arlen, P. M., Camphausen, K., Mohebtash, M., Kamrava, M., Schlom, J., & Citrin, D. (2011) · Expert Opinion on Biological Therapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 26